Which has better earnings & valuation, KRRO or RADX?

Radiopharm Theranostics has lower revenue, but higher earnings than Korro Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $6.39M 31.10 -$117.26M -$10.00 N/A Radiopharm Theranostics $2.35M 15.61 -$24.83M N/A N/A

Which has higher earnings and valuation, RADX or CRBU?

Radiopharm Theranostics has higher earnings, but lower revenue than Caribou Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 15.61 -$24.83M N/A N/A Caribou Biosciences $11.16M 14.75 -$148.12M -$1.42 N/A

Which has stronger earnings and valuation, RADX or HUMA?

Radiopharm Theranostics has higher revenue and earnings than Humacyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 15.61 -$24.83M N/A N/A Humacyte $2.04M 81.03 -$40.83M -$0.57 N/A

Which has stronger earnings & valuation, RADX or IMDX?

Radiopharm Theranostics has higher earnings, but lower revenue than Oncocyte. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 15.61 -$24.83M N/A N/A Oncocyte $4.05M 38.03 -$50.22M -$1.48 N/A

Is RADX or IMDX more profitable?

Radiopharm Theranostics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Oncocyte -2,454.64% N/A -96.96%

Which has better earnings and valuation, RADX or EQ?

Equillium has higher revenue and earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 15.61 -$24.83M N/A N/A Equillium $41.10M 3.37 -$22.40M -$0.32 N/A

Is RADX or EQ more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Equillium's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Equillium N/A -61.43% -53.72%

Radiopharm Theranostics (RADX) Competitors

$2.80 0.00 (0.00%)

As of 03:59 PM Eastern

Compare

RADX vs. KRRO, CRBU, HUMA, IMDX, and EQ

Should you buy Radiopharm Theranostics stock or one of its competitors? Radiopharm Theranostics's main competitors and comparable companies include Korro Bio (KRRO), Caribou Biosciences (CRBU), Humacyte (HUMA), Oncocyte (IMDX), and Equillium (EQ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Radiopharm Theranostics compare to Korro Bio?

Korro Bio (NASDAQ:KRRO) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Korro Bio has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

Radiopharm Theranostics has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Radiopharm Theranostics' return on equity of 0.00% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-114.26%	-68.57%
Radiopharm Theranostics	N/A	N/A	N/A

In the previous week, Korro Bio had 6 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 6 mentions for Korro Bio and 0 mentions for Radiopharm Theranostics. Korro Bio's average media sentiment score of 0.50 beat Radiopharm Theranostics' score of 0.00 indicating that Korro Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Korro Bio	Positive
Radiopharm Theranostics	Neutral

Radiopharm Theranostics has lower revenue, but higher earnings than Korro Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	31.10	-$117.26M	-$10.00	N/A
Radiopharm Theranostics	$2.35M	15.61	-$24.83M	N/A	N/A

13.2% of Korro Bio shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Korro Bio presently has a consensus price target of $16.71, indicating a potential upside of 23.90%. Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 292.86%. Given Radiopharm Theranostics' higher probable upside, analysts clearly believe Radiopharm Theranostics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Korro Bio beats Radiopharm Theranostics on 10 of the 15 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Caribou Biosciences?

Radiopharm Theranostics (NASDAQ:RADX) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Radiopharm Theranostics has higher earnings, but lower revenue than Caribou Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	15.61	-$24.83M	N/A	N/A
Caribou Biosciences	$11.16M	14.75	-$148.12M	-$1.42	N/A

Radiopharm Theranostics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Radiopharm Theranostics' return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

In the previous week, Caribou Biosciences had 2 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Caribou Biosciences and 0 mentions for Radiopharm Theranostics. Caribou Biosciences' average media sentiment score of 0.77 beat Radiopharm Theranostics' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Caribou Biosciences	Positive

Radiopharm Theranostics has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

Radiopharm Theranostics currently has a consensus price target of $11.00, indicating a potential upside of 292.86%. Caribou Biosciences has a consensus price target of $8.67, indicating a potential upside of 422.09%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

77.5% of Caribou Biosciences shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Caribou Biosciences beats Radiopharm Theranostics on 9 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Humacyte?

Radiopharm Theranostics (NASDAQ:RADX) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

In the previous week, Humacyte had 2 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Humacyte and 0 mentions for Radiopharm Theranostics. Humacyte's average media sentiment score of 0.66 beat Radiopharm Theranostics' score of 0.00 indicating that Humacyte is being referred to more favorably in the news media.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Humacyte	Positive

Radiopharm Theranostics has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. Radiopharm Theranostics' return on equity of 0.00% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Humacyte	-4,836.06%	-2,914.18%	-89.45%

44.7% of Humacyte shares are owned by institutional investors. 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Radiopharm Theranostics currently has a consensus price target of $11.00, suggesting a potential upside of 292.86%. Humacyte has a consensus price target of $6.25, suggesting a potential upside of 739.49%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Radiopharm Theranostics has higher revenue and earnings than Humacyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	15.61	-$24.83M	N/A	N/A
Humacyte	$2.04M	81.03	-$40.83M	-$0.57	N/A

Radiopharm Theranostics has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, Humacyte has a beta of 2.54, suggesting that its share price is 154% more volatile than the broader market.

Summary

Humacyte beats Radiopharm Theranostics on 9 of the 14 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Oncocyte?

Radiopharm Theranostics (NASDAQ:RADX) and Oncocyte (NASDAQ:IMDX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Radiopharm Theranostics has higher earnings, but lower revenue than Oncocyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	15.61	-$24.83M	N/A	N/A
Oncocyte	$4.05M	38.03	-$50.22M	-$1.48	N/A

In the previous week, Oncocyte had 3 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 3 mentions for Oncocyte and 0 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.00 equaled Oncocyte'saverage media sentiment score.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Oncocyte	Neutral

Radiopharm Theranostics presently has a consensus target price of $11.00, suggesting a potential upside of 292.86%. Oncocyte has a consensus target price of $12.00, suggesting a potential upside of 151.57%. Given Radiopharm Theranostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Radiopharm Theranostics is more favorable than Oncocyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

55.4% of Oncocyte shares are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Radiopharm Theranostics has a net margin of 0.00% compared to Oncocyte's net margin of -2,454.64%.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Oncocyte	-2,454.64%	N/A	-96.96%

Radiopharm Theranostics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Oncocyte has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Summary

Radiopharm Theranostics and Oncocyte tied by winning 6 of the 12 factors compared between the two stocks.

How does Radiopharm Theranostics compare to Equillium?

Radiopharm Theranostics (NASDAQ:RADX) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Radiopharm Theranostics' return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Equillium	N/A	-61.43%	-53.72%

Radiopharm Theranostics presently has a consensus target price of $11.00, indicating a potential upside of 292.86%. Equillium has a consensus target price of $7.57, indicating a potential upside of 245.73%. Given Radiopharm Theranostics' higher possible upside, equities research analysts clearly believe Radiopharm Theranostics is more favorable than Equillium.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Equillium	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.82

27.1% of Equillium shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Equillium has higher revenue and earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	15.61	-$24.83M	N/A	N/A
Equillium	$41.10M	3.37	-$22.40M	-$0.32	N/A

Radiopharm Theranostics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Equillium has a beta of 1.83, indicating that its stock price is 83% more volatile than the broader market.

In the previous week, Equillium had 4 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 4 mentions for Equillium and 0 mentions for Radiopharm Theranostics. Equillium's average media sentiment score of 0.59 beat Radiopharm Theranostics' score of 0.00 indicating that Equillium is being referred to more favorably in the news media.

Company	Overall Sentiment
Radiopharm Theranostics	Neutral
Equillium	Positive

Summary

Equillium beats Radiopharm Theranostics on 10 of the 14 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RADX vs. The Competition

Export

Metric	Radiopharm Theranostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.67M	$3.70B	$7.02B	$12.98B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	N/A	9.09	269.19	24.71
Price / Sales	15.61	1,255.18	588.76	97.69
Price / Cash	N/A	44.95	28.89	37.42
Price / Book	0.80	17.66	11.27	6.42
Net Income	-$24.83M	-$13.25M	$3.45B	$347.03M
7 Day Performance	-9.97%	5.36%	3.56%	2.49%
1 Month Performance	-35.93%	-1.74%	-0.58%	-1.04%
1 Year Performance	-40.17%	61.36%	77.52%	23.22%

Radiopharm Theranostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RADX Radiopharm Theranostics	2.9896 of 5 stars	$2.80 flat	$11.00 +292.9%	-40.2%	$36.67M	$2.35M	N/A	N/A	Gap Down
KRRO Korro Bio	2.7975 of 5 stars	$10.37 -0.8%	$16.71 +61.2%	-17.2%	$150.72M	$6.39M	N/A	70	Earnings Report Analyst Upgrade
CRBU Caribou Biosciences	1.9283 of 5 stars	$1.46 -3.3%	$8.67 +493.6%	-4.6%	$149.76M	$11.16M	N/A	100	Upcoming Earnings
HUMA Humacyte	3.6161 of 5 stars	$0.65 -2.7%	$6.25 +856.5%	-71.0%	$149.11M	$2.04M	N/A	150	Upcoming Earnings
IMDX Oncocyte	1.2404 of 5 stars	$4.65 +1.1%	$12.00 +158.1%	N/A	$148.54M	$4.05M	N/A	120	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RADX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Radiopharm Theranostics (RADX) Competitors

RADX vs. KRRO, CRBU, HUMA, IMDX, and EQ

How does Radiopharm Theranostics compare to Korro Bio?

Summary

How does Radiopharm Theranostics compare to Caribou Biosciences?

Summary

How does Radiopharm Theranostics compare to Humacyte?

Summary

How does Radiopharm Theranostics compare to Oncocyte?

Summary

How does Radiopharm Theranostics compare to Equillium?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Radiopharm Theranostics (RADX) Competitors

RADX vs. KRRO, CRBU, HUMA, IMDX, and EQ

How does Radiopharm Theranostics compare to Korro Bio?

Which has more risk and volatility, KRRO or RADX?

Is KRRO or RADX more profitable?

Does the media refer more to KRRO or RADX?

Which has better earnings & valuation, KRRO or RADX?

Do institutionals & insiders have more ownership in KRRO or RADX?

Do analysts rate KRRO or RADX?

Summary

How does Radiopharm Theranostics compare to Caribou Biosciences?

Which has higher earnings and valuation, RADX or CRBU?

Is RADX or CRBU more profitable?

Does the media favor RADX or CRBU?

Which has more volatility & risk, RADX or CRBU?

Do analysts recommend RADX or CRBU?

Do insiders and institutionals believe in RADX or CRBU?

Summary

How does Radiopharm Theranostics compare to Humacyte?

Does the media favor RADX or HUMA?

Is RADX or HUMA more profitable?

Do institutionals and insiders hold more shares of RADX or HUMA?

Do analysts recommend RADX or HUMA?

Which has stronger earnings and valuation, RADX or HUMA?

Which has more volatility and risk, RADX or HUMA?

Summary

How does Radiopharm Theranostics compare to Oncocyte?

Which has stronger earnings & valuation, RADX or IMDX?

Does the media favor RADX or IMDX?

Do analysts rate RADX or IMDX?

Do insiders and institutionals have more ownership in RADX or IMDX?

Is RADX or IMDX more profitable?

Which has more volatility and risk, RADX or IMDX?

Summary

How does Radiopharm Theranostics compare to Equillium?

Is RADX or EQ more profitable?

Do analysts prefer RADX or EQ?

Do institutionals and insiders believe in RADX or EQ?

Which has better earnings and valuation, RADX or EQ?

Which has more volatility and risk, RADX or EQ?

Does the media prefer RADX or EQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX vs. The Competition

Radiopharm Theranostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools